Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...

Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes M6P ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate in prostate cancer: London, UK Tuesday, October 28, 2025, 09:00 Hrs [IST] GSK plc and Syndivia, a private b ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a ...

EMA grants Orphan Drug Designation to GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 to treat pulmonary neuroendocrine carcinoma: London, UK Wednesday, October 29, 2025 ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...